keyword
MENU ▼
Read by QxMD icon Read
search

clinical oncology

keyword
https://www.readbyqxmd.com/read/28449033/response-assessment-in-medulloblastoma-and-leptomeningeal-seeding-tumors-recommendations-from-the-response-assessment-in-pediatric-neuro-oncology-committee
#1
Katherine E Warren, Gilbert Vezina, Tina Y Poussaint, Monika Warmuth-Metz, Marc C Chamberlain, Roger J Packer, Alba A Brandes, Moshe Reiss, Stewart Goldman, Michael J Fisher, Ian F Pollack, Michael D Prados, Patrick Y Wen, Susan M Chang, Christelle Dufour, David Zurakowski, Rolf D Kortmann, Mark W Kieran
Lack of standard response criteria in clinical trials for medulloblastoma and other seeding tumors complicates assessment of therapeutic efficacy and comparisons across studies. An international working group was established to develop consensus recommendations for response assessment. The aim is that these recommendations be prospectively evaluated in clinical trials, with the goal of achieving more reliable risk stratification and uniformity across clinical trials. Current practices and literature review were performed to identify major confounding issues and justify subsequently developed recommendations; in areas lacking scientific investigations, recommendations were based on experience of committee members and consensus was reached after discussion...
April 25, 2017: Neuro-oncology
https://www.readbyqxmd.com/read/28448782/amcp-partnership-forum-driving-value-and-outcomes-in-oncology
#2
(no author information available yet)
Innovation in cancer treatment has provided a wealth of recently available therapeutic agents and a healthy drug pipeline that promises to change the way we approach this disease and the lives of those affected in the years to come. However, the majority of these new agents, many of which are targeted to specific genomic features of various tumors, may challenge the health care system's ability to afford cancer care. This innovation drives the need to focus on the value of the treatments provided to patients with cancer and on methods to optimize the efficiency of the dollars we spend, in addition to the clinical value itself...
May 2017: Journal of Managed Care & Specialty Pharmacy
https://www.readbyqxmd.com/read/28448747/a-hierarchical-bayesian-design-for-randomized-phase-ii-clinical-trials-with-multiple-groups
#3
Jun Yin, Rui Qin, Daniel J Sargent, Charles Erlichman, Qian Shi
Enhanced knowledge of the biological and genetic basis of cancer is re-defining target population for new treatments. In oncology, potential targets for a new therapeutic agent often include various solid and hematologic malignancies that share common signaling pathways. New agents are often tested in multiple tumor types across which information can be borrowed. We propose a hierarchical Bayesian design (HBD) to simultaneously test a novel agent in multiple groups for randomized phase II clinical trials with binary endpoints...
April 27, 2017: Journal of Biopharmaceutical Statistics
https://www.readbyqxmd.com/read/28448269/circulating-cell-free-micrornas-as-clinical-cancer-biomarkers
#4
REVIEW
Virginie Armand-Labit, Anne Pradines
MicroRNAs (miRNAs) are non-coding small RNAs that are master regulators of genic expression and consequently of many cellular processes. But their expression is often deregulated in human tumors leading to cancer development. Recently miRNAs were discovered in body fluids (serum, plasma and others) and their levels have often been reported to be altered in patients. Circulating miRNAs became one of the most promising biomarkers in oncology for early diagnosis, prognosis and therapeutic response prediction. Here we describe the origins and roles of miRNAs, and summarize the most recent studies focusing on their usefulness as cancer biomarkers in lung, breast, colon, prostate, ovary cancers and melanoma...
April 27, 2017: Biomolecular Concepts
https://www.readbyqxmd.com/read/28448239/extranodal-marginal-zone-lymphoma-no-longer-just-a-sidekick
#5
Manali K Kamdar, Sonali M Smith
The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and a summary of the authors' suggested management approaches. The goal of this series is to help readers better understand how to apply the results of key studies, including those published in Journal of Clinical Oncology, to patients seen in their own clinical practice...
April 27, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28447341/chemotherapy-alone-versus-chemotherapy-plus-radiotherapy-for-adults-with-early-stage-hodgkin-lymphoma
#6
REVIEW
Oliver Blank, Bastian von Tresckow, Ina Monsef, Lena Specht, Andreas Engert, Nicole Skoetz
BACKGROUND: Combined modality treatment consisting of chemotherapy followed by localised radiotherapy is the standard treatment for patients with early stage Hodgkin lymphoma (HL). However, due to long- term adverse effects such as secondary malignancies the role of radiotherapy has been questioned recently and some clinical study groups advocate chemotherapy only for this indication. OBJECTIVES: To assess the effects of chemotherapy alone compared to chemotherapy plus radiotherapy in adults with early stage HL ...
April 27, 2017: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/28447257/recent-developments-in-radiotherapy-for-small-cell-lung-cancer-a-review-by-the-oncologic-group-for-the-study-of-lung-cancer-spanish-radiation-oncology-society
#7
REVIEW
N Rodriguez de Dios, P Calvo, M Rico, M Martín, F Couñago, A Sotoca, B Taboada, A Rodríguez
Small-cell lung cancer (SCLC) accounts for 13% of all lung tumours. The standard treatment in patients with limited-stage disease is radiotherapy combined with chemotherapy. In extensive SCLC, the importance of consolidation thoracic radiotherapy in patients with a good treatment response has become increasingly recognized. In both limited and extensive disease, prophylactic cranial irradiation is recommended in patients who respond to treatment. New therapeutic approaches such as immunotherapy are being increasingly incorporated into the treatment of SCLC, although more slowly than in non-small cell lung cancer (NSCLC)...
April 26, 2017: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/28447222/feeding-strategies-in-pediatric-cancer-patients-with-gastrointestinal-mucositis-a-multicenter-prospective-observational-study-and-international-survey
#8
Nicoline S S Kuiken, Edmond H H M Rings, Marry M van den Heuvel-Eibrink, Marianne D van de Wetering, Wim J E Tissing
INTRODUCTION: Currently, there is no adequate prevention or treatment for both oral and gastrointestinal mucositis induced by chemotherapy and/or radiotherapy. Supportive care of symptoms plays a primary role during mucositis in the pediatric clinical setting. We aimed to get insight in the currently used feeding strategies in clinical practice in pediatric cancer patients with chemotherapy-induced mucositis. METHODS: A prospective observational study was performed to identify feeding strategies after chemotherapy courses causing mucositis in almost all patients at the University Medical Center Groningen (UMCG), the Academic Medical Center Amsterdam (AMC), and the Princess Maxima Center Utrecht (PMC)...
April 26, 2017: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/28447024/following-the-preclinical-data-leveraging-the-abscopal-effect-more-efficaciously
#9
Wilfred Ngwa, Zi Ouyang
Radiotherapy is employed in the treatment of over 50% of cancer patients. However, this therapy approach is limited to mainly treating localized disease. In 1953, Mole described the remarkable abscopal effect, whereby, localized radiotherapy of a patient's primary tumor might engender regression of cancer at distant sites, which were not irradiated. Current consensus is that if the abscopal effect can be efficaciously leveraged, it would transform the field of radiation oncology, extending the use of radiotherapy to treatment of both localized and metastatic disease...
2017: Frontiers in Oncology
https://www.readbyqxmd.com/read/28446532/next-generation-sequencing-ngs-analysis-on-single-circulating-tumor-cells-ctcs-with-no-need-of-whole-genome-amplification-wga
#10
Raffaele Palmirotta, Domenica Lovero, Erica Silvestris, Claudia Felici, Davide Quaresmini, Paola Cafforio, Franco Silvestris
BACKGROUND: Isolation and genotyping of circulating tumor cells (CTCs) is gaining an increasing interest by clinical researchers in oncology not only for investigative purposes, but also for concrete application in clinical practice in terms of diagnosis, prognosis and decision treatment with targeted therapies. For the mutational analysis of single CTCs, the most advanced biotechnology methodology currently available includes the combination of whole genome amplification (WGA) followed by next-generation sequencing (NGS)...
May 2017: Cancer Genomics & Proteomics
https://www.readbyqxmd.com/read/28446507/the-microbiota-a-new-variable-impacting-cancer-treatment-outcomes
#11
Jessica L Fessler, Thomas F Gajewski
Preclinical evidence has established that the host commensal microbiota can contribute to therapeutic response in cancer models, a finding supported by early clinical data.  This connection between the microbiome and clinical outcome in oncology is cause for new consideration in the administration of antibiotics and microbiota-modulating interventions to improve outcomes.
April 26, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/28446463/the-national-cancer-institute-almanac-a-comprehensive-screening-resource-for-the-detection-of-anticancer-drug-pairs-with-enhanced-therapeutic-activity
#12
Susan L Holbeck, Richard Camalier, James A Crowell, Jeevan Prasaad Govindharajulu, Melinda G Hollingshead, Lawrence W Anderson, Eric C Polley, Larry Rubinstein, Apurva K Srivastava, Deborah F Wilsker, Jerry M Collins, James H Doroshow
To date, over 100 small molecule oncology drugs have been approved by the US Food and Drug Administration.  Due to the inherent heterogeneity of tumors, these small molecules are often administered in combination to prevent emergence of resistant cell subpopulations.  Therefore, new combination strategies to overcome drug resistance in patients with advanced cancer are needed.  In this study, we performed a systematic evaluation of the therapeutic activity of over 5,000 pairs of FDA-approved cancer drugs against a panel of 60 well-characterized human tumor cell lines (NCI-60) to uncover combinations with greater than additive growth-inhibitory activity...
April 26, 2017: Cancer Research
https://www.readbyqxmd.com/read/28445101/second-line-hormonal-therapy-for-men-with-chemotherapy-na%C3%A3-ve-castration-resistant-prostate-cancer-american-society-of-clinical-oncology-provisional-clinical-opinion-summary
#13
Katherine S Virgo, R Bryan Rumble, Eric A Singer
No abstract text is available yet for this article.
April 26, 2017: Journal of Oncology Practice
https://www.readbyqxmd.com/read/28445098/comparative-analysis-of-human-epidermal-growth-factor-receptor-2-testing-in-breast-cancer-according-to-2007-and-2013-american-society-of-clinical-oncology-college-of-american-pathologists-guideline-recommendations
#14
Wedad M Hanna, Elzbieta Slodkowska, Fang-I Lu, Houman Nafisi, Sharon Nofech-Mozes
Purpose To study the effect of the 2013 updates to the 2007 American Society of Clinical Oncology/College of American Pathologists recommendations for human epidermal growth factor receptor 2 (HER2) testing in breast cancer on testing patterns and interpretation in a large regional reference laboratory. Patients and Methods Patient cases with HER2 testing scores for breast biomarker evaluation were selected from our laboratory information system during two 12-month periods (2012 and 2014). The number of tests performed, type of specimens, proportion of HER2-positive and equivocal patient cases, and number of repeat tests on subsequent excisional specimens were examined and compared...
April 26, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28444889/invasive-fungal-infections-in-paediatric-patients-treated-with-macromolecular-immunomodulators-other-than-tumour-necrosis-alpha-inhibitors
#15
REVIEW
Ioannis Kyriakidis, Athanasios Tragiannidis, Ilse Zündorf, Andreas H Groll
An expanding list of immunomodulatory or immunosuppressive monoclonal antibodies (mAbs) and biologic therapeutics is currently entering clinical practice, particularly in the areas of oncology, transplantation and autoimmune disorders. These agents are directed against molecules or cells involved in inflammation and immunity and may therefore be associated with serious and opportunistic infections. The purpose of this review was to critically analyse the literature on invasive fungal infections (IFIs) occurring in association with mAbs and fusion proteins other than tumour necrosis alpha (TNF-α) inhibitors, including therapeutics modulating T-cell-mediated pathologies (muromonab, abatacept, belatacept, ipilimumab, basiliximab, daclizumab), inducing lymphopenia (alemtuzumab), depleting CD20+ B cells (rituximab) and interfering with various targets (anakinra, natalizumab, blodalumab, ixekizumab and others) with a focus on children, and to provide a framework of evaluating the risk for IFIs in this population...
April 26, 2017: Mycoses
https://www.readbyqxmd.com/read/28444532/the-utrecht-cohort-for-multiple-breast-cancer-intervention-studies-and-long-term-evaluation-umbrella-objectives-design-and-baseline-results
#16
D A Young-Afat, C H van Gils, H J G D van den Bongard, H M Verkooijen
PURPOSE: In oncology, RCTs are often beset by slow recruitment, limited generalizability, and strong preferences for interventions by patients and physicians. The cohort multiple randomized controlled trial (cmRCT) is an innovative design with the potential to overcome those challenges. In cmRCT, a prospective cohort serves as an infrastructure for multiple RCTs. We implemented cmRCT in a clinical breast cancer setting by creating UMBRELLA-a large prospective cohort of breast cancer and DCIS patients/survivors...
April 25, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28444414/-general-diagnostic-work-up-for-benign-tumors-of-the-musculoskeletal-system
#17
REVIEW
J Panotopoulos, P Th Funovics, R Windhager
INTRODUCTION: Benign bone tumors are heterogeneous and have different biological behaviors. Treatment requires knowledge of the principle diagnosis and clinical behavior to avoid, on the one hand, overtreatment and, on the other hand, incorrect diagnosis of a potentially malignant tumor. METHODS: Bone tumors of stage I (according to Enneking) should be observed clinically and radiologically. For stage II and stage III lesions, a biopsy should be performed, based on the corresponding oncological guidelines...
April 25, 2017: Der Orthopäde
https://www.readbyqxmd.com/read/28444102/pet-mri-a-novel-hybrid-imaging-technique-major-clinical-indications-and-preliminary-experience-in-brazil
#18
Taise Vitor, Karine Minaif Martins, Tudor Mihai Ionescu, Marcelo Livorsi da Cunha, Ronaldo Hueb Baroni, Marcio Ricardo Taveira Garcia, Jairo Wagner, Guilherme de Carvalho Campos, Solange Amorim Nogueira, Elaine Gonçalves Guerra, Edson Amaro
In recent years, medical imaging with hybrid techniques has widely accepted and employed in clinical routine. PET/MRI offers significant advantages, including excellent contrast and resolution and reduced ionizing radiation, as compared to well-established PET/CT. Therefore, PET/MRI is a promising modality for oncologic imaging of some regions, such as brain, head and neck, liver and pelvis. This article set out to analyze clinical conditions that could benefit from PET/MRI imaging based on our caseload. The potential of PET/MRI to become the imaging modality of choice for assessment of neurologic and oncologic conditions associated with soft tissues is highlighted...
January 2017: Einstein
https://www.readbyqxmd.com/read/28443893/trail-np-hybrids-for-cancer-therapy-a-review
#19
REVIEW
H Belkahla, G Herlem, F Picaud, T Gharbi, M Hémadi, S Ammar, O Micheau
Cancer is a worldwide health problem. It is now considered as a leading cause of morbidity and mortality in developed countries. In the last few decades, considerable progress has been made in anti-cancer therapies, allowing the cure of patients suffering from this disease, or at least helping to prolong their lives. Several cancers, such as those of the lung and pancreas, are still devastating in the absence of therapeutic options. In the early 90s, TRAIL (Tumor Necrosis Factor-related apoptosis-inducing ligand), a cytokine belonging to the TNF superfamily, attracted major interest in oncology owing to its selective anti-tumor properties...
April 26, 2017: Nanoscale
https://www.readbyqxmd.com/read/28443588/solitary-fibrous-tumors-of-chest-another-look-with-the-oncologic-perspective
#20
Mert Saynak, Nirmal K Veeramachaneni, Jessica L Hubbs, Dilruba Okumuş, Lawrence B Marks
B Solitary fibrous tumors (SFT) are mesenchymal lesions that arise at a variety of sites, most commonly the pleura. Most patients are asymptomatic at diagnosis, with lesions being detected incidentally. Nevertheless, some patients present due to symptoms from local tumor compression (eg. of the airways and pulmonary parenchyma). Furthermore, radiological methods are not always conclusive in making a diagnosis, and thus, pathological analysis is often required. In the past three decades, immunohistochemical techniques have provided a gold standard in SFT diagnosis...
April 6, 2017: Balkan Medical Journal
keyword
keyword
85701
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"